2015
DOI: 10.1097/mog.0000000000000203
|View full text |Cite
|
Sign up to set email alerts
|

Primary endoscopic therapies for obesity and metabolic diseases

Abstract: http://links.lww.com/COG/A12.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
6
0
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 49 publications
(40 reference statements)
0
6
0
1
Order By: Relevance
“…The drug only lasts 3-6 months [39]. A meta-analysis including 115 patients found a significant decrease in weight from before to after the injection of botulinum toxin A, as well as a significant decrease in weight in patients treated with botulinum toxin A relative to patients injected with a placebo.…”
Section: Intragastric Botulinum Toxin Injections (Fda Status: Not Appmentioning
confidence: 95%
See 1 more Smart Citation
“…The drug only lasts 3-6 months [39]. A meta-analysis including 115 patients found a significant decrease in weight from before to after the injection of botulinum toxin A, as well as a significant decrease in weight in patients treated with botulinum toxin A relative to patients injected with a placebo.…”
Section: Intragastric Botulinum Toxin Injections (Fda Status: Not Appmentioning
confidence: 95%
“…It accomplishes thermal ablation either through the use of radiofrequency [6] or a recirculating hotwater-filled balloon [39]. To date, weight loss data associated with this intervention has not been reported in a published trial.…”
Section: Duodenal Mucosal Resurfacing (Fda Status: Not Approved)mentioning
confidence: 99%
“…Randomisiert kontrollierte Studien berichten einen deutlichen Vorteil des Endo-Barriers™ von 0,9-1,7 %-Punkten Unterschied im Vergleich zu Kontrollgruppen bezüglich der Verbesserung des HbA 1c (24)(25)(26)(27)…”
Section: Aspirationstherapieunclassified
“…Information about the effect of endoscopic bariatric therapies on NAFLD and MetS is mainly derived from the intragastric balloon procedures. Published data reported excess weight loss percentage between 11% and 55% after endoscopically placed intragastric balloons; however, this device has to be removed 6 months after its placement [71]. Some studies demonstrate a decrease of 42.9% to 15.1% in the proportion of patients with NAFLD and MetS [72,73].…”
mentioning
confidence: 95%
“…Gastric interventions include intragastric balloon, transpyloric shuttle, endoscopic sleeve gastroplasty, articulating circular stapler, aspiration therapy and, intragastric injection of botulinum toxin A. Small bowel interventions encompass duodeno-jejunal bypass sleeve (endobarrier), gastro-duodeno-jejunal bypass sleeve (valentx) and, duodenal mucosal resurfacing [71]. Information about the effect of endoscopic bariatric therapies on NAFLD and MetS is mainly derived from the intragastric balloon procedures.…”
mentioning
confidence: 99%